Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 17 | 2026 | 755 | 2.630 |
Why?
|
| Anemia, Sickle Cell | 5 | 2023 | 187 | 1.630 |
Why?
|
| Sickle Cell Trait | 2 | 2022 | 19 | 1.440 |
Why?
|
| Serum Albumin | 4 | 2024 | 59 | 0.990 |
Why?
|
| Protein Phosphatase 1 | 8 | 2025 | 70 | 0.890 |
Why?
|
| Virus Replication | 8 | 2025 | 318 | 0.830 |
Why?
|
| HIV Infections | 9 | 2025 | 2586 | 0.830 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2024 | 241 | 0.730 |
Why?
|
| Cyclin-Dependent Kinase 9 | 5 | 2021 | 37 | 0.630 |
Why?
|
| Gene Expression Regulation, Viral | 6 | 2021 | 113 | 0.630 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 539 | 0.610 |
Why?
|
| Cyclin-Dependent Kinase 2 | 4 | 2018 | 32 | 0.590 |
Why?
|
| Glycosylation | 5 | 2024 | 113 | 0.540 |
Why?
|
| Anti-HIV Agents | 3 | 2017 | 486 | 0.500 |
Why?
|
| Iron Chelating Agents | 2 | 2017 | 21 | 0.470 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 57 | 0.460 |
Why?
|
| Ebolavirus | 3 | 2025 | 49 | 0.460 |
Why?
|
| Transcription, Genetic | 7 | 2022 | 592 | 0.450 |
Why?
|
| Curcumin | 2 | 2017 | 118 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2024 | 92 | 0.440 |
Why?
|
| Mucins | 2 | 2026 | 73 | 0.420 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 2021 | 55 | 0.420 |
Why?
|
| I-kappa B Kinase | 1 | 2014 | 51 | 0.420 |
Why?
|
| Antiviral Agents | 4 | 2022 | 195 | 0.400 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2025 | 247 | 0.400 |
Why?
|
| Prediabetic State | 2 | 2024 | 69 | 0.390 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 386 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 760 | 0.360 |
Why?
|
| Humans | 28 | 2026 | 43102 | 0.340 |
Why?
|
| Viral Proteins | 3 | 2025 | 190 | 0.330 |
Why?
|
| Mannose | 2 | 2026 | 32 | 0.280 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 193 | 0.270 |
Why?
|
| Macrophages | 3 | 2020 | 529 | 0.240 |
Why?
|
| Hemolysis | 2 | 2023 | 60 | 0.230 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 184 | 0.230 |
Why?
|
| Nucleoproteins | 1 | 2025 | 15 | 0.230 |
Why?
|
| Pilot Projects | 2 | 2024 | 760 | 0.220 |
Why?
|
| Trypsin | 1 | 2024 | 40 | 0.220 |
Why?
|
| Capsid | 1 | 2025 | 65 | 0.220 |
Why?
|
| Heme Oxygenase-1 | 2 | 2015 | 52 | 0.220 |
Why?
|
| Protein Multimerization | 1 | 2025 | 115 | 0.210 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 115 | 0.210 |
Why?
|
| Iron | 2 | 2023 | 251 | 0.200 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 10 | 0.200 |
Why?
|
| Chromatography, Liquid | 1 | 2024 | 182 | 0.200 |
Why?
|
| Phosphorylation | 7 | 2022 | 986 | 0.200 |
Why?
|
| Host-Pathogen Interactions | 3 | 2020 | 209 | 0.190 |
Why?
|
| Cyclin T | 3 | 2021 | 16 | 0.190 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 457 | 0.190 |
Why?
|
| RNA, Viral | 4 | 2021 | 321 | 0.190 |
Why?
|
| Computational Biology | 1 | 2025 | 327 | 0.190 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2021 | 17 | 0.180 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 280 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2023 | 201 | 0.170 |
Why?
|
| Animals | 12 | 2026 | 16992 | 0.160 |
Why?
|
| Viruses | 1 | 2020 | 39 | 0.160 |
Why?
|
| Serine | 2 | 2018 | 79 | 0.160 |
Why?
|
| Cells, Cultured | 4 | 2018 | 1621 | 0.160 |
Why?
|
| Quinolines | 1 | 2020 | 78 | 0.160 |
Why?
|
| Mice | 7 | 2023 | 6644 | 0.160 |
Why?
|
| Glucose | 1 | 2021 | 244 | 0.150 |
Why?
|
| Chromomycins | 1 | 2019 | 1 | 0.150 |
Why?
|
| Streptomyces | 1 | 2019 | 22 | 0.150 |
Why?
|
| Kidney | 2 | 2020 | 372 | 0.150 |
Why?
|
| Drug Stability | 2 | 2018 | 129 | 0.150 |
Why?
|
| Protein Binding | 5 | 2025 | 1082 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 29 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2018 | 26 | 0.140 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 15 | 0.140 |
Why?
|
| Pyridones | 1 | 2018 | 50 | 0.130 |
Why?
|
| Oxidative Stress | 2 | 2024 | 1003 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 263 | 0.120 |
Why?
|
| Enzyme Induction | 1 | 2015 | 52 | 0.120 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2015 | 35 | 0.120 |
Why?
|
| Half-Life | 1 | 2015 | 63 | 0.120 |
Why?
|
| Proviruses | 1 | 2015 | 35 | 0.120 |
Why?
|
| Virus Activation | 1 | 2015 | 38 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2023 | 329 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2015 | 55 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 432 | 0.110 |
Why?
|
| Cyclin A | 1 | 2014 | 4 | 0.110 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2026 | 54 | 0.110 |
Why?
|
| Reverse Transcription | 1 | 2014 | 23 | 0.110 |
Why?
|
| Cyclin E | 1 | 2014 | 14 | 0.110 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 17 | 0.110 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 19 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2015 | 91 | 0.110 |
Why?
|
| Urea | 1 | 2014 | 46 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 56 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 42 | 0.110 |
Why?
|
| Transfection | 1 | 2015 | 532 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 2 | 2026 | 127 | 0.100 |
Why?
|
| Cell Survival | 2 | 2014 | 945 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2018 | 735 | 0.100 |
Why?
|
| Cell Line | 2 | 2014 | 1410 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2024 | 185 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 187 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1271 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 72 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 61 | 0.100 |
Why?
|
| Adenovirus E4 Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Genes, Viral | 1 | 2012 | 61 | 0.090 |
Why?
|
| Chemokines | 1 | 2013 | 96 | 0.090 |
Why?
|
| Serpins | 1 | 2012 | 27 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 34 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1124 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2024 | 389 | 0.090 |
Why?
|
| Eye Proteins | 1 | 2012 | 63 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 239 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2024 | 1285 | 0.080 |
Why?
|
| Female | 5 | 2024 | 24698 | 0.080 |
Why?
|
| Virion | 1 | 2026 | 75 | 0.060 |
Why?
|
| Obesity | 2 | 2024 | 1151 | 0.060 |
Why?
|
| Swine | 1 | 2026 | 212 | 0.060 |
Why?
|
| Workflow | 1 | 2025 | 26 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2026 | 388 | 0.060 |
Why?
|
| Protein Conformation | 2 | 2018 | 416 | 0.050 |
Why?
|
| Positive Transcriptional Elongation Factor B | 2 | 2015 | 15 | 0.050 |
Why?
|
| Proteomics | 2 | 2017 | 378 | 0.050 |
Why?
|
| HIV Antibodies | 1 | 2023 | 24 | 0.050 |
Why?
|
| Maillard Reaction | 1 | 2023 | 7 | 0.050 |
Why?
|
| Cysteine | 1 | 2024 | 103 | 0.050 |
Why?
|
| Models, Biological | 2 | 2018 | 712 | 0.050 |
Why?
|
| Metformin | 1 | 2024 | 75 | 0.050 |
Why?
|
| Middle Aged | 3 | 2024 | 12222 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2022 | 42 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2018 | 876 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 196 | 0.050 |
Why?
|
| Adult | 3 | 2024 | 13872 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 216 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1063 | 0.040 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2020 | 7 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 62 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2025 | 704 | 0.040 |
Why?
|
| Mutation | 2 | 2018 | 1177 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2020 | 72 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2020 | 57 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 2020 | 23 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 141 | 0.040 |
Why?
|
| NADP | 1 | 2019 | 37 | 0.040 |
Why?
|
| Oxygen | 1 | 2020 | 218 | 0.040 |
Why?
|
| Glycolysis | 1 | 2019 | 71 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2018 | 11 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2018 | 118 | 0.040 |
Why?
|
| Male | 3 | 2024 | 23409 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 701 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2019 | 168 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2018 | 62 | 0.030 |
Why?
|
| Proteins | 1 | 2020 | 382 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 665 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 934 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 189 | 0.030 |
Why?
|
| Lung | 1 | 2020 | 492 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2015 | 33 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 1180 | 0.030 |
Why?
|
| Virus Latency | 1 | 2015 | 49 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 186 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 2014 | 14 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2014 | 168 | 0.030 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1596 | 0.030 |
Why?
|
| Vero Cells | 1 | 2014 | 112 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2023 | 2157 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 49 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2015 | 358 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 80 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 154 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 247 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 462 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 213 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1035 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 8214 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1081 | 0.020 |
Why?
|